The Effectiveness of Myo-Inositol and D-Chiro Inositol Treatment in Type 2 Diabetes

Inositol has been used as a supplement in treating several pathologies such as PCOS, metabolic syndrome, and gestational diabetes. Both myo-inositol and its isomer d-chiro-inositol showed insulin mimetic effects in conditions of insulin resistance. Type 2 diabetes (T2DM) is a condition typically cau...

Full description

Saved in:
Bibliographic Details
Published in:International Journal of Endocrinology 2016-01, Vol.2016 (2016), p.360-364-141
Main Authors: Pintaudi, Basilio, Bonomo, Matteo, Di Vieste, Giacoma
Format: Article
Language:English
Subjects:
Antihypertensives
Blood pressure
Cardiac stress tests
Cholesterol
Complications and side effects
Diabetes
Disease
Dosage and administration
Drug therapy
Drugs
Endocrinology
Fasting
Feasibility studies
Gender
Glucose
Inositol
Insulin resistance
Lipids
Low density lipoprotein
Metabolism
Performance evaluation
Physiology
Pregnancy
Triglycerides
Type 2 diabetes
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Inositol has been used as a supplement in treating several pathologies such as PCOS, metabolic syndrome, and gestational diabetes. Both myo-inositol and its isomer d-chiro-inositol showed insulin mimetic effects in conditions of insulin resistance. Type 2 diabetes (T2DM) is a condition typically caused by insulin resistance. There is a lack of evidence of inositol use in T2DM. We evaluated the effectiveness and safety of myo-inositol and d-chiro-inositol treatment in T2DM. This was a pilot study involving a consecutive sample of patients with T2DM with suboptimal glycemic control (HbA1c 7.0–10.0%) already treated with glucose-lowering agents. Patients (23.1% males, mean age of 60.8 ± 11.7 years) took for three months a combination of myo-inositol (550 mg) and d-chiro-inositol (13.8 mg) orally twice a day as add-on supplement to their glucose-lowering drugs. Possible occurrence of side effects was investigated. After three months of treatment fasting blood glucose ( 192.6 ± 60.2 versus 160.9 ± 36.4 ; p = 0.02 ) and HbA1c levels ( 8.6 ± 0.9 versus 7.7 ± 0.9 ; p = 0.02 ) significantly decreased compared to baseline. There was no significant difference in blood pressure, lipid profile, and BMI levels. None of the participants reported side effects. In conclusion, a supplementation with a combination of myo- and d-chiro-inositol is an effective and safe strategy for improving glycemic control in T2DM.
ISSN:1687-8337
1687-8345
DOI:10.1155/2016/9132052